25 c) Le curetage-électrocoagulation, p.26 ,
69 a) Caractéristiques démographiques, 69 b) Caractéristiques cliniques et histologiques au diagnostic, p.70 ,
72 a) Efficacité du traitement, p.74 ,
Prise en charge diagnostique et th??rapeutique du carcinome cutan?? basocellulaire ??? Analyse des recommandations, Annales de Chirurgie Plastique Esth??tique, vol.57, issue.2, pp.92-105, 2012. ,
DOI : 10.1016/j.anplas.2012.01.004
Vismodegib, Clinical Cancer Research, vol.18, issue.12, pp.3218-3240, 2012. ,
DOI : 10.1158/1078-0432.CCR-12-0568
Aggressive basal cell carcinoma: Presentation, pathogenesis, and management, Cancer and Metastasis Reviews, vol.23, issue.3/4, pp.3-4389, 2004. ,
DOI : 10.1023/B:CANC.0000031775.04618.30
Advanced Basal Cell Carcinoma: Epidemiology and Therapeutic Innovations, Current Dermatology Reports, vol.126, issue.12, pp.40-45, 2014. ,
DOI : 10.1007/s13671-014-0069-y
Basal-Cell Carcinoma, New England Journal of Medicine, vol.353, issue.21, pp.2262-2271, 2005. ,
DOI : 10.1056/NEJMra044151
Metastatic Basal Cell Carcinoma: Report of Two Cases and Literature Review, Journal of Cutaneous Medicine and Surgery, vol.34, issue.1, pp.10-15, 2005. ,
DOI : 10.1007/s10227-005-0027-1
Management of basal cell carcinoma in adults Clinical practice guidelines, Eur J Dermatol, vol.16, issue.4, pp.394-401, 2006. ,
Marges d???ex??r??se chirurgicale et taux de r??cidive des carcinomes cutan??s, Annales de Chirurgie Plastique Esth??tique, vol.53, issue.5, pp.389-98, 2008. ,
DOI : 10.1016/j.anplas.2007.07.015
Treatments of advanced basal cell carcinoma: a review of the literature, G Ital Dermatol E Venereol Organo Uff Soc Ital Dermatol E Sifilogr, 2014. ,
Surgical excision versus Mohs' micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years' follow-up, The Lancet Oncology, vol.9, issue.12, pp.1149-56, 2008. ,
DOI : 10.1016/S1470-2045(08)70260-2
Evaluation of Cosmetic Results of a Randomized Trial Comparing Surgery and Radiotherapy in the Treatment of Basal Cell Carcinoma of the Face, Plastic & Reconstructive Surgery, vol.105, issue.7, pp.2544-51, 2000. ,
DOI : 10.1097/00006534-200006000-00039
Syndrome de Gorlin??: la phototh??rapie dynamique, technique compl??mentaire du traitement chirurgical, Annales de Chirurgie Plastique Esth??tique, vol.57, issue.2, pp.173-179, 2012. ,
DOI : 10.1016/j.anplas.2011.07.002
Basal cell carcinoma-treatments for the commonest skin cancer, Dtsch Ärztebl Int, vol.111, issue.22, pp.389-95, 2014. ,
Update of cetuximab for non-melanoma skin cancer, Expert Opinion on Biological Therapy, vol.35, issue.5, pp.271-277, 2014. ,
DOI : 10.1007/s00066-013-0378-2
Hedgehog: functions and mechanisms, Genes & Development, vol.22, issue.18, pp.2454-72, 2008. ,
DOI : 10.1101/gad.1693608
Hedgehog signalling, Current Biology, vol.18, issue.6, pp.238-279, 2008. ,
DOI : 10.1016/j.cub.2008.01.050
Multiple roles for lipids in the Hedgehog signalling pathway, Nature Reviews Molecular Cell Biology, vol.133, issue.9, pp.437-482, 2008. ,
DOI : 10.1038/nrm2414
Extensive phosphorylation of Smoothened in Hedgehog pathway activation, Proceedings of the National Academy of Sciences, vol.101, issue.52, pp.17900-17907, 2004. ,
DOI : 10.1073/pnas.0408093101
Decoding the phosphorylation code in Hedgehog signal transduction, Cell Research, vol.21, issue.2, pp.186-200, 2013. ,
DOI : 10.1038/cr.2013.10
Hedgehog signalling: how to get from Smo to Ci and Gli, Trends in Cell Biology, vol.16, issue.4, pp.176-80, 2006. ,
DOI : 10.1016/j.tcb.2006.02.004
Metabolites in vertebrate Hedgehog signaling, Biochemical and Biophysical Research Communications, vol.446, issue.3, pp.669-74, 2014. ,
DOI : 10.1016/j.bbrc.2014.01.087
Canonical and non-canonical Hedgehog signalling and the control of metabolism, Seminars in Cell & Developmental Biology, vol.33, pp.81-92, 2014. ,
DOI : 10.1016/j.semcdb.2014.05.007
Noncanonical Hedgehog Signaling, Vitam Horm, vol.88, pp.55-72, 2012. ,
DOI : 10.1016/B978-0-12-394622-5.00003-1
Nonclassical hedgehog-gli signaling and its clinical implications, International Journal of Cancer, vol.16, issue.1, pp.1-6, 2014. ,
DOI : 10.1002/ijc.28424
Hedgehog signals regulate multiple aspects of gastrointestinal development, Dev Camb Engl, vol.127, issue.12, pp.2763-72, 2000. ,
Characterization of a Novel Fibroblast Growth Factor 10 (Fgf10) Knock-In Mouse Line to Target Mesenchymal Progenitors during Embryonic Development, PLoS ONE, vol.7, issue.6, p.38452, 2012. ,
DOI : 10.1371/journal.pone.0038452.s001
Shh Signaling and Regulatory Gene Expression in Mouse Taste Buds, Chemical Senses, vol.30, issue.Supplement 1, pp.50-51, 2005. ,
DOI : 10.1093/chemse/bjh108
1 Developmental roles and clinical significance of Hedgehog signaling, Curr Top Dev Biol, vol.53, pp.1-114, 2003. ,
DOI : 10.1016/S0070-2153(03)53002-2
Gorlin-Goltz syndrome, Annals of Medical and Health Sciences Research, vol.4, issue.2, pp.279-82, 2014. ,
DOI : 10.4103/2141-9248.129064
Loss-of-function mutations in the human GLI2 gene are associated with pituitary anomalies and holoprosencephaly-like features, Proceedings of the National Academy of Sciences, vol.100, issue.23, pp.13424-13433, 2003. ,
DOI : 10.1073/pnas.2235734100
Unraveling the therapeutic potential of the Hedgehog pathway in cancer, Nature Medicine, vol.31, issue.11, pp.1410-1432, 2013. ,
DOI : 10.1002/mpo.10121
Mechanisms of Hedgehog pathway activation in cancer and implications for therapy, Trends in Pharmacological Sciences, vol.30, issue.6, pp.303-315, 2009. ,
DOI : 10.1016/j.tips.2009.03.007
Novel receptor antagonists for cancer therapy: hedgehog pathway inhibitors, Drug Discovery Today: Therapeutic Strategies, vol.6, issue.2, pp.63-72, 2009. ,
DOI : 10.1016/j.ddstr.2009.07.001
Basal cell carcinomas: attack of the hedgehog, Nature Reviews Cancer, vol.14, issue.10, pp.743-54, 2008. ,
DOI : 10.1001/jama.294.6.681
Effects of teratogenic agents in range plants, Cancer Res, vol.28, issue.11, pp.2323-2329, 1968. ,
Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened, Genes & Development, vol.16, issue.21, pp.2743-2751, 2002. ,
DOI : 10.1101/gad.1025302
Modulators of the hedgehog signaling pathway, Bioorganic & Medicinal Chemistry, vol.18, issue.18, pp.6613-6637, 2010. ,
DOI : 10.1016/j.bmc.2010.07.038
Targeting the Hedgehog signaling pathway for cancer therapy, Expert Opinion on Therapeutic Targets, vol.70, issue.1, pp.49-66, 2012. ,
DOI : 10.1371/journal.pbio.0040232
Targeting of Smoothened for therapeutic gain, Trends in Pharmacological Sciences, vol.35, issue.5, pp.237-283, 2014. ,
DOI : 10.1016/j.tips.2014.03.002
URL : https://hal.archives-ouvertes.fr/hal-01055292
Vismodegib and the Hedgehog Pathway: A New Treatment for Basal Cell Carcinoma, Clinical Therapeutics, vol.34, issue.10, pp.2039-50, 2012. ,
DOI : 10.1016/j.clinthera.2012.08.011
Hedgehog signaling pathway: A novel target for cancer therapy: Vismodegib, a promising therapeutic option in treatment of basal cell carcinomas, Indian Journal of Pharmacology, vol.46, issue.1, pp.3-12, 2014. ,
DOI : 10.4103/0253-7613.124884
Vismodegib: A smoothened inhibitor for the treatment of advanced basal cell carcinoma, Indian Dermatology Online Journal, vol.4, issue.4, pp.365-373, 2013. ,
DOI : 10.4103/2229-5178.120685
Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects, British Journal of Clinical Pharmacology, vol.4, issue.1, pp.788-96, 2012. ,
DOI : 10.1111/j.1365-2125.2012.04281.x
Pharmacokinetics of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors: the Role of Alpha-1-Acid Glycoprotein Binding, Clinical Cancer Research, vol.17, issue.8, pp.2512-2532, 2011. ,
DOI : 10.1158/1078-0432.CCR-10-2736
Pharmacokinetic Dose-Scheduling Study of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors, Clinical Cancer Research, vol.17, issue.17, pp.5774-82, 2011. ,
DOI : 10.1158/1078-0432.CCR-11-0972
Evaluation of Food Effect on Pharmacokinetics of Vismodegib in Advanced Solid Tumor Patients, Clinical Cancer Research, vol.19, issue.11, pp.3059-67, 2013. ,
DOI : 10.1158/1078-0432.CCR-12-3829
Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma, New England Journal of Medicine, vol.361, issue.12, pp.1164-72, 2009. ,
DOI : 10.1056/NEJMoa0905360
Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma, New England Journal of Medicine, vol.366, issue.23, pp.2171-2180, 2012. ,
DOI : 10.1056/NEJMoa1113713
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), European Journal of Cancer, vol.45, issue.2, pp.228-275, 2009. ,
DOI : 10.1016/j.ejca.2008.10.026
Inhibiting the Hedgehog Pathway in Patients with the Basal-Cell Nevus Syndrome, New England Journal of Medicine, vol.366, issue.23, pp.2180-2188, 2012. ,
DOI : 10.1056/NEJMoa1113538
Vismodegib (V), un inhibiteur de la voie Hedgehog (HPI), dans le carcinome basocellulaire avanc?? (CBCa)??: analyse interm??diaire de l?????tude STEVIE, Annales de Dermatologie et de V??n??r??ologie, vol.140, issue.12, p.394, 2013. ,
DOI : 10.1016/j.annder.2013.09.073
Disponible sur: http, p.132555 ,
-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide), an orally bioavailable systemic Hedgehog signalling pathway inhibitor, Xenobiotica, vol.422, issue.11, pp.850-61, 2009. ,
DOI : 10.1593/neo.81264
Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug???drug interaction potential, Cancer Chemotherapy and Pharmacology, vol.276, issue.suppl 8, pp.193-202, 2013. ,
DOI : 10.1007/s00280-012-1996-6
Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449, New England Journal of Medicine, vol.361, issue.12, pp.1173-1181, 2009. ,
DOI : 10.1056/NEJMoa0902903
Smoothened Mutation Confers Resistance to a Hedgehog Pathway Inhibitor in Medulloblastoma, Science, vol.326, issue.5952, pp.572-576, 2009. ,
DOI : 10.1126/science.1179386
Small Molecule Inhibition of GDC-0449 Refractory Smoothened Mutants and Downstream Mechanisms of Drug Resistance, Cancer Research, vol.71, issue.2, pp.435-479, 2011. ,
DOI : 10.1158/0008-5472.CAN-10-2876
Emergence of chemoresistance in a metastatic basal cell carcinoma patient after complete response to hedgehog pathway inhibitor vismodegib (GDC-0449), Australasian Journal of Dermatology, vol.148, issue.3, pp.218-239, 2014. ,
DOI : 10.1111/ajd.12196
Initial Assessment of Tumor Regrowth After Vismodegib in Advanced Basal Cell Carcinoma, Archives of Dermatology, vol.148, issue.11, pp.1324-1329, 2012. ,
DOI : 10.1001/archdermatol.2012.2354
Hedgehog Fights Back: Mechanisms of Acquired Resistance against Smoothened Antagonists, Cancer Research, vol.71, issue.15, pp.5057-61, 2011. ,
DOI : 10.1158/0008-5472.CAN-11-0923
Acquired resistance to the Hedgehog pathway inhibitor vismodegib due to smoothened mutations in treatment of locally advanced basal cell carcinoma, Journal of the American Academy of Dermatology, vol.71, issue.5, 2014. ,
DOI : 10.1016/j.jaad.2014.08.001
Genome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response to Smoothened Inhibition, Cancer Cell, vol.25, issue.3, pp.393-405, 2014. ,
DOI : 10.1016/j.ccr.2014.02.004
Targeting Hedgehog signaling and understanding refractory response to treatment with Hedgehog pathway inhibitors, Drug Resistance Updates, vol.15, issue.4, pp.211-233, 2012. ,
DOI : 10.1016/j.drup.2012.05.002
Itraconazole and Arsenic Trioxide Inhibit Hedgehog Pathway Activation and Tumor Growth Associated with Acquired Resistance to Smoothened Antagonists, Cancer Cell, vol.23, issue.1, pp.23-34, 2013. ,
DOI : 10.1016/j.ccr.2012.11.017
Inhibition mechanism exploration of investigational drug TAK-441 as inhibitor against Vismodegib-resistant Smoothened mutant, European Journal of Pharmacology, vol.723, pp.305-318, 2014. ,
DOI : 10.1016/j.ejphar.2013.11.014
Interfering with Resistance to Smoothened Antagonists by Inhibition of the PI3K Pathway in Medulloblastoma, Science Translational Medicine, vol.2, issue.51 ,
DOI : 10.1126/scitranslmed.3001599
Expanded access study of patients with advanced basal??cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib, Journal of the American Academy of Dermatology, vol.70, issue.1, pp.60-69, 2014. ,
DOI : 10.1016/j.jaad.2013.09.012
Vismodegib in the treatment of advanced BCC, Ir Med J, vol.107, issue.7, pp.215-221, 2014. ,
Vismodegib-associated hepatotoxicity: A potential side effect detected in postmarketing surveillance, Journal of the American Academy of Dermatology, vol.71, issue.2, pp.397-405, 2014. ,
DOI : 10.1016/j.jaad.2014.04.023
An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma, Journal of the American Academy of Dermatology, vol.71, issue.5, 2014. ,
DOI : 10.1016/j.jaad.2014.05.020
Multiple Shh signaling centers participate in fungiform papilla and taste bud formation and maintenance, Developmental Biology, vol.382, issue.1, pp.82-97, 2013. ,
DOI : 10.1016/j.ydbio.2013.07.022
Sonic hedgehog gene therapy increases the ability of the dystrophic skeletal muscle to regenerate after injury, Gene Therapy, vol.126, issue.4 ,
DOI : 10.1016/j.exger.2013.06.005
Shh maintains dermal papilla identity and hair morphogenesis via a Noggin-Shh regulatory loop, Genes & Development, vol.26, issue.11, pp.1235-1281, 2012. ,
DOI : 10.1101/gad.187401.112
Nouvelle r??ponse d???un carcinome basocellulaire au vismodegib, Annales de Dermatologie et de V??n??r??ologie, vol.140, issue.12, p.448, 2013. ,
DOI : 10.1016/j.annder.2013.09.200
Indications and Limitations of Vismodegib for Basal Cell Carcinoma???Reply, JAMA Ophthalmology, vol.132, issue.7, p.906, 2014. ,
DOI : 10.1001/jamaophthalmol.2014.1805
Compassionate use of vismodegib and adjuvant radiotherapy in the treatment of multiple locally advanced and inoperable basal cell carcinomas and squamous cell carcinomas of the skin, Journal of the American Academy of Dermatology, vol.70, issue.4, pp.88-97, 2014. ,
DOI : 10.1016/j.jaad.2013.11.032
Vismodegib as Eye-Sparing Adjuvant Treatment for Orbital Basal Cell Carcinoma, JAMA Ophthalmology, vol.131, issue.10, pp.1364-1370, 2013. ,
DOI : 10.1001/jamaophthalmol.2013.4430